Avinger OCT-Guided Technologies Featured at AMP 2021
REDWOOD CITY, CA / ACCESSWIRE / August 16, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced presentations featuring the Company's Lumivascular, OCT-guided, technologies at the annual AMP (Amputation Prevention Symposium) conference occurring last week.
AMP focuses on education and technologies for treating critical limb ischemia (CLI), an advanced stage of PAD, in patients facing a life-altering amputation. The conference features lectures by internationally recognized faculty, live case symposia, hands-on workshops, and exhibits supporting the mission of amputation prevention.
Dr. Jaafer Golzar, an interventional cardiologist and endovascular specialist with Advocate Medical Group and Avinger's Chief Medical Officer, was a member of faculty and invited to present during the session "Atherectomy & CLI: Why Does CLI Need Atherectomy?". Dr. Golzar shared case experience and outcomes with Avinger's Pantheris SV and new Tigereye image-guided catheters and highlighted upcoming clinical data releases for Avinger's atherectomy catheters in his presentation "OCT-Directed Atherectomy: The Latest Update".
Avinger's Pantheris OCT-guided atherectomy catheters were also featured in a hands-on Atherectomy Workshop held at the conference, during which demonstrations were conducted and physicians were able to experience Pantheris in an arterial atherectomy model.
Commenting on his presentation at the AMP conference and new tools to treat critical limb ischemia, Dr. Golzar noted, "Onboard OCT-guidance provides tremendous benefits for the treatment of below-the-knee lesions and difficult-to-treat applications. Given the robust safety profile and ability to optimally debulk lesions, I believe Pantheris SV represents the most advanced tool available to treat patients suffering from critical limb ischemia with the goal of preventing the need for amputation. Future data releases from Avinger's IMAGE-BTK trial assessing Pantheris SV in below-the-knee interventions and the INSIGHT in-stent restenosis trial should further validate the safety and efficacy of OCT-guided therapy in prospective, multi-center settings."
Jeff Soinski, Avinger's President and CEO, commented, "The AMP conference is one of the preeminent platforms for advancing the treatment of clinical limb ischemia and amputation prevention for patients suffering from late-stage peripheral artery disease. We are honored to have our technology featured on the podium of such an impactful symposium. The continued expansion of Pantheris SV users and procedures indicates to us that the interventional community is embracing this device as a powerful tool for addressing CLI."
Avinger's proprietary Lumivascular technology allows physicians, for the first time ever, to see from inside the artery during an atherectomy or CTO crossing procedure by using an imaging modality called optical coherence tomography, or OCT, that is displayed on Avinger's Lightbox console. Physicians performing atherectomy or crossing CTOs with other devices must rely solely on X-ray and tactile feedback to guide their interventions while treating complicated arterial disease. With the Lumivascular approach, physicians can more accurately navigate their devices and treat PAD lesions, due to real-time OCT images generated from inside the artery, without exposing healthcare workers and patients to the negative effects of ionizing radiation.
About Avinger, Inc.
Avinger is a commercial-stage medical device company that designs and develops the first and only image-guided, catheter-based system for the diagnosis and treatment of patients with Peripheral Artery Disease (PAD). PAD is estimated to affect over 12 million people in the U.S. and over 200 million worldwide. Avinger is dedicated to radically changing the way vascular disease is treated through its Lumivascular platform, which currently consists of the Lightbox imaging console, the Ocelot and Tigereye™ family of chronic total occlusion (CTO) catheters, and the Pantheris® family of atherectomy devices. Avinger is based in Redwood City, California. For more information, please visit www.avinger.com.
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the potential benefits of our products for patients and healthcare providers, the timing and outcome of results from our IMAGE-BTK and INSIGHT trial, and the timing and extent of acceptance and use of our products by healthcare providers. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include our dependency on a limited number of products; the resource requirements related to Pantheris, Tigereye and our Lightbox imaging console; the outcome of clinical trial results; as well as the other risks described in the section entitled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 11, 2021 and in our other reports filed with the Securities and Exchange Commission, including our Quarterly Reports on Form 10-Q. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Avinger disclaims any obligation to update these forward-looking statements.
Chief Financial Officer
Darrow Associates Investor Relations
SOURCE: Avinger, Inc.
View source version on accesswire.com: